Drug Trial Radar · NCT05983068
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Apr 29, 2027
Study completion May 19, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping (STS) in approximately 48 pediatric participants (aged ≥6 and \<15 years at study entry) with moderate-to-severe AD. All eligible participants with AD will be treated with Dupixent® for 104 weeks according to locally approved Dupixent® product label (in country/region where the study is conducted). After the 104-week treatment phase and the last assessment at the End of Treatment (EoT), participants will be followed-up for 4 weeks and an End-of-Study (EoS) visit by telephone at 4 weeks after the EoT visit will end the study for each participant. The maximum duration of the study per participant will be 112 weeks (including screening period). The study population will include approximately 48 pediatric participants with AD for long-term treatment with dupilumab: * Treatment cohort 1 - newly recruited participants with AD (aged ≥6 to \<12 years at study entry) * Treatment cohort 2 - any former PELISTAD participants (from the previous 16-week treatment study \[PELISTAD/LPS16764\] who consent to participate in this long-term study; aged ≥6 to \<15 years at entry to this study)
Conditions
- Dermatitis Atopic
Interventions
dupilumabDrug
solution for injection; by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in TEWL after 5 STS assessed on lesional skin.Time frame: Baseline to Week 104
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
National Jewish Health Medical Center- Site Number : 8400001
Denver, Colorado
SSM Health Saint Louis University Hospital- Site Number : 8400006
St Louis, Missouri
NYU Langone Medical Center- Site Number : 8400004
New York, New York
Investigational Site Number : 8260001
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.